Evidence map›Paper›PMID 28629419›Full record

ArticleRespiratory research2017

Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).

Sean Duffy, Robert Marron, Helen Voelker, Richard Albert, John Connett, William Bailey, Richard Casaburi, J Allen Cooper, Jeffrey L Curtis, Mark Dransfield and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2019
    Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 15 institutions in 2 countries.

Sean DuffyDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. sean.duffy2@tuhs.temple.edu.
Robert MarronDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Helen VoelkerUniversity of Minnesota, Minneapolis, MN, USA.
Richard AlbertDenver Health Medical Center, Denver, CO, USA.
John ConnettUniversity of Minnesota, Minneapolis, MN, USA.
William BaileyUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Richard CasaburiLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
J Allen CooperUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Jeffrey L CurtisUniversity of Michigan Health System, Ann Arbor, MI, USA.
Mark DransfieldUniversity of Alabama at Birmingham, Birmingham, AL, USA.
MeiLan K HanUniversity of Michigan Health System, Ann Arbor, MI, USA.
Barry MakeNational Jewish Health, Denver, CO, USA.
Nathaniel MarchettiDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Fernando MartinezWeill Cornell Medical College of Cornell University, New York, NY, USA.
Stephen LazarusUniv of California San Francisco, San Francisco, CA, USA.
Dennis NiewoehnerMinneapolis VA Medical Center, Minneapolis, MN, USA.
Paul D ScanlonMayo Clinic, Rochester, MN, USA.
Frank SciurbaUniversity of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Steven ScharfUniversity of Maryland, Baltimore, MD, USA.
Robert M ReedUniversity of Maryland, Baltimore, MD, USA.
George WashkoBrigham & Women's Hospital, Boston, MA, USA.
Prescott WoodruffUniv of California San Francisco, San Francisco, CA, USA.
Charlene McEvoyHealthPartners, Saint Paul, MN, USA.
Shawn AaronThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Don SinProvidence Heart + Lung Institute, Vancouver, BC, Canada.
Gerard J CrinerDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
NIH COPD Clinical Research Network and the Canadian Institutes of Health Research
Temple University · USUniversity of Alabama at Birmingham · USMichigan Medicine · USUniversity of Maryland, Baltimore · USUniversity of Minnesota · USBrigham and Women's Hospital · USCornell University · USDenver Health Medical Center · USHarbor–UCLA Medical Center · USHealthPartners · USMayo Clinic in Arizona · USMinneapolis VA Medical Center · USOttawa Hospital Research InstituteUniversity of Colorado Denver · USUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBeta-blockers are commonly prescribed for patients with cardiovascular disease. Providers have been wary of treating chronic obstructive pulmonary disease (COPD) patients with beta-blockers due to concern for bronchospasm, but retrospective studies have shown that cardio-selective beta-blockers are safe in COPD and possibly beneficial. However, these benefits may reflect symptom improvements due to the cardiac effects of the medication. The purpose of this study is to evaluate associations between beta-blocker use and both exacerbation rates and longitudinal measures of lung function in two well-characterized COPD cohorts.

methodsWe retrospectively analyzed 1219 participants with over 180 days of follow up from the STATCOPE trial, which excluded most cardiac comorbidities, and from the placebo arm of the MACRO trial. Primary endpoints were exacerbation rates per person-year and change in spirometry over time in association with beta blocker use.

resultsOverall 13.9% (170/1219) of participants reported taking beta-blockers at enrollment. We found no statistically significant differences in exacerbation rates with respect to beta-blocker use regardless of the prevalence of cardiac comorbidities. In the MACRO cohort, patients taking beta-blockers had an exacerbation rate of 1.72/person-year versus a rate of 1.71/person-year in patients not taking beta-blockers. In the STATCOPE cohort, patients taking beta-blockers had an exacerbation rate of 1.14/person-year. Patients without beta-blockers had an exacerbation rate of 1.34/person-year. We found no detrimental effect of beta blockers with respect to change in lung function over time.

conclusionWe found no evidence that beta-blocker use was unsafe or associated with worse pulmonary outcomes in study participants with moderate to severe COPD.

Indexed as

Adrenergic beta-AntagonistsAgedCohort StudiesFemaleFollow-Up StudiesHumansLungMaleMiddle AgedPulmonary Disease, Chronic ObstructiveRespiratory Function TestsRetrospective StudiesTreatment OutcomeAdrenergic beta-AntagonistsBeta-blockerCOPDExacerbation

Identifiers

PMID28629419
PMCPMC5477165
OpenAlexW2668004123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.